GLP-1 Agonist Therapy Center

A proper baseline assessment for GLP-1 therapy has become a critical yet sometimes overlooked step in modern diabetes care. In fast-moving clinical environments, especially with the rise of telehealth, providers may feel pressure to initiate GLP-1 therapy quickly. However, skipping essential baseline evaluations can lead to missed risks, poor outcomes, …

GLP-1 therapies are becoming an important focus in peripheral artery disease, especially as clinicians look beyond glucose control to improve outcomes in high-risk patients. People with diabetes and peripheral artery disease often face a difficult path, marked by poor circulation, delayed wound healing, and a higher risk of amputation. While …

Disease progression in patients using GLP-1 therapies is becoming a critical topic as these medications continue to reshape diabetes care. While GLP-1 receptor agonists improve glycemic control and support weight loss, could they also be hiding deeper metabolic decline? Much like a polished surface that conceals underlying cracks, improved lab …

GLP-1 receptor agonists as adjunct therapy in type 1 diabetes are gaining attention as clinicians look for new ways to improve glycemic control. But is this approach a promising tool or a risky shortcut? As emerging evidence builds, providers must balance potential benefits with safety concerns and patient-specific factors. Table …

Telehealth prescribing of GLP-1 medications is rapidly reshaping how diabetes and weight management care is delivered. But as access expands, an important question emerges: who is truly managing patient care? Like a relay race without a clear handoff, patients often move between providers, platforms, and pharmacies without consistent oversight. As …

The risk of side effects with GLP-1 therapies varies widely among patients, yet treatment decisions often overlook this variability. Why do some patients tolerate GLP-1 receptor agonists with ease while others discontinue early? Much like how individuals respond differently to diet or exercise, medication tolerance is influenced by a mix …

The rise of newer incretin-based therapies is changing how clinicians think about diabetes care. But are GLP-1 receptor agonists already being challenged by this next wave of incretin therapy? While these medications have transformed treatment in recent years, newer multi-agonist therapies are gaining attention. As a result, healthcare providers are …

What does success really look like with GLP-1 therapy in 2026? Is it simply lowering A1C, or are clinicians now aiming for something more sustainable like remission or long-term maintenance? As GLP-1 receptor agonists continue to transform diabetes care, the conversation is shifting beyond short-term outcomes. Today, defining clear and …

GLP-1 dose escalation is quickly becoming a central topic in diabetes care, especially as higher dosing strategies gain traction. But are we truly entering a high-dose era, or simply refining how we use these powerful agents? As clinicians face patients who plateau on standard regimens, the question becomes not just …

GLP-1 dose escalation is becoming a critical topic as demand for these therapies continues to surge. From semaglutide (Ozempic, Wegovy) to tirzepatide (Mounjaro), these medications are reshaping diabetes and weight management. However, are clinicians and patients moving faster than the evidence supports? As real-world practices evolve, dosing strategies often stray …